Chemistry:Vociprotafib
From HandWiki
Vociprotafib (RMC-4630) is a drug that acts as an inhibitor of the protein tyrosine phosphatase enzyme SHP-2 (PTPN11). It has been researched for the treatment of cancer and has seen some early stage clinical trials in humans.[1][2][3]
References
- ↑ "Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway". Cancer Research 80 (16_Supplement): 1943. 2020. doi:10.1158/1538-7445.AM2020-1943.
- ↑ "Targeting BRAF pathway in low-grade serous ovarian cancer". Journal of Gynecologic Oncology 35 (4). July 2024. doi:10.3802/jgo.2024.35.e104. PMID 38768941.
- ↑ "Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer". The Lancet. Respiratory Medicine. November 2025. doi:10.1016/S2213-2600(25)00298-X. PMID 41325754.
 |  |
